Cargando…
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
Multiple myeloma is an incurable malignancy of plasma B-cells. Traditional chemotherapeutic regimes often induce initial tumor regression; however, virtually all patients eventually succumb to relapse caused by either reintroduction of disease during autologous transplant or expansion of chemotherap...
Autores principales: | Bartee, Eric, Bartee, Mee Y, Bogen, Bjarne, Yu, Xue-Zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142464/ https://www.ncbi.nlm.nih.gov/pubmed/27933316 http://dx.doi.org/10.1038/mto.2016.32 |
Ejemplares similares
-
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
por: Burton, Chase, et al.
Publicado: (2019) -
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022) -
Potential of oncolytic viruses in the treatment of multiple myeloma
por: Bartee, Eric
Publicado: (2018) -
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
por: Dryja, Parker, et al.
Publicado: (2023) -
Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
por: Thomas, Raquela J., et al.
Publicado: (2023)